Xeloda - Capecitabine

Xeloda (capecitabine) prescribing information. Roche Laboratories, Inc. www.gene.com/gene/products/information/xeloda, revised Nov. 2009, accessed Dec. 1,2009. 

Fareston - toremifene Oncaspar- pegaspargase Xeloda - capecitabine... 

Xeloda (Capecitabine) product information. Roche Pharmaceuticals, April 2003. 

O Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (Capecitabine) (Meeting abstract). Proc Am Soc Clin Oncol 2000 A400. 

An example of how PopPK analyses are reported in the product label can be found in the product label for Xeloda (capecitabine), which is manufactured by Hoff-man-La Roche ... 

Xeloda (Capecitabine). Roche Products Ltd. UK Summary of product characteristics, March 2007. 

Capecitabine (Xeloda ) Orally active prodrug of 5-fluorouracil. Once activated, the mechanism of action is the same. Similar to continuous infusion 5-fluorouracil... 

Capecitabine (Xeloda ) Cytotoxic nucleoside Breast (then colorectal) Phase II. On the basis of response rate. Then randomized Phase III for survival... 

Role of p53 in 5-FU-Induced Radiosensitization Role of 5-FU Radiosensitization in Gene Therapy Oral Forms of 5-FU Capecitabine (Xeloda) in Combination with Radiation Therapy Clinical Indications... 

The recent availability of oral formulations of 5-FU, may provide not only an improvement in the ease of administration and the efficacy of fluoropyrimidine therapy, but also alleviate complications related to the catheters. Such agents include uracil tegafur (UFT) and capecitabine (Xeloda). 

CAPECITABINE (XELODA) IN COMBINATION WITH RADIATION THERAPY... 

A number of fluoropyrimidines other than 5-FU have been s mthesized, most of which act as prodrugs for 5-FU. Capecitabine (Xeloda ) is an orally administered fluorop5Tim-idine that is converted to 5-FU by the enzyme thymidine phosphorylase (TP), which is often over-expressed in malignant compared to normal tissues (29). Capecitabine has been shown to be equivalent to 5-FU/LV and was the first oral agent to be approved by the FDA for the treatment of mCRC (30). 

Generic Name Capecitabine Trade Name Xeloda Primary Antineoplastic lndication(s) Breast cancer Common Adverse Effects Blood disorders [anemia, neutropenia, thrombocytopenia] Gl distress [abdominal pain, nausea, vomiting] dermatitis stomatitis unusual tiredness... 

In summary, capecitabine (1), an A -carbamate pyrimidine nucleoside prodrug of cytotoxic antimetabolite 5-fluorouracil, is an FDA-approved anticancer drug that can be administered orally. This compound uses a multilayer of prodrug strategies that not only avoids side effects arising from exposure of toxic metabolites to healthy tissue but is converted to 5-fluorouracil only by enzymes preferentially expressed in many cancer cell types, thus resulting in selective delivery of the drug to tumors. Capecitabine is marketed under the trade name of Xeloda for use in the treatment of metastatic colorectal and breast cancers and metastatic breast cancer that is resistant to paclitaxel or anthracycline therapies. 

Chapter 5. Capecitabine (Xeloda) An Oral Chemotherapy Agent... 

Capecitabine (Xeloda) Breast cancer colorectal cancer Cl tract cancers... 

Fluorouracil (5-FU) is a cytotoxic agent used to treat solid tumours, such as those of the breast and colon. However, its prodrug capecitabine (Xeloda) is much better absorbed orally. 5-FU, applied as a cream, is also very useful for the treatment of certain skin cancers. It is significant that 8% of the population lack an enzyme that can metabolise 5-FU. In these people, administration of normal doses of the drug can lead to dangerously high toxic levels in the blood. 

---